Biolinq’s Post

Historically, the venture capital industry has overlooked weight-loss solutions – but the advent of GLP-1 medications has changed the landscape rapidly over the past few years.   Dennis McWilliams shares his perspective on the shift towards these treatments in a new Bloomberg article, highlighting recent developmental efforts to produce options with more tolerable side effects. Additionally, as patients often regain weight after stopping these drugs, companies are looking to create new strategies in managing this transition without rebounding.   While it seems that every major pharma company now has their own obesity strategy, Dennis provides thoughts on where to invest in what has become a crowded market.   https://lnkd.in/eHSqdsAG

❓ How do you develop connected therapeutics that improve patient outcomes while safeguarding #sustainability? SHL Medical solves such a complex problem with a simple solution: Molly® Connected Cap. During a presentation in Japan, SHL’s Nagisa Kobashi highlighted the sustainability aspect of our Molly Connected Cap – a compact, retrofittable autoinjector cap add-on that records and transmits data on patients’ use of the product. The device is designed with a focus on process optimization as it leverages the modularity of Molly’s infrastructure. Beyond that, the Connected Cap’s pre-injection removal ensures the separation of the module from any contaminated part. Watch the clip 🎬 to understand what other benefits Molly Connected Cap can bring for pharma and biotech companies. #DrugDelivery #ThoughtLeader #DigitalHealth

📍 Biopharma Blueprint - Revenue Realignment: After riding the pandemic’s “sugar high,” the biopharma landscape is now finding its equilibrium. In 2022, public biotech company revenues were down 1% from the previous year. The soaring demand for COVID-related products once supercharged the sector, but now we’re settling into a new phase. Despite this, factoring out COVID products from the portfolios of leading biotechs, the industry’s revenues saw a modest 3.7% increase in 2022. Is this a sign of stabilization or a pause before another leap? One thing’s certain: Continued innovation is key to growth.

🚀 Exciting news - DelSiTech Ltd has secured €10M in funding to revolutionize drug delivery! Their groundbreaking Silica Matrix technology promises extended and controlled release of medications, offering new hope for patient treatments. Get ready for a healthcare transformation! #Innovation #HealthTech #DrugDelivery #BiotechInvestment #DelSiTech 🧬💡💊 [Link to your blog post]

Every year, #Scrip gathers predictions from around 300 #biopharma executives and experts. The resulting “Scrip Asks” series is one of our best-read features, outlining the industry’s view of the coming year in a range of important areas, including financing, deal-making, transformative technology, clinical trial trends, therapeutic area trends, manufacturing and more. #freecontent #CitelineCommercial #financing #transformativetechnology #clinicaltrial

Peter Keeling is Founder and CEO of Diaceutics PLC, a company on an idea hatched at MIT's Sloan School in the mid 1990s -that the integration of therapy and diagnostic commercialisation will bring transformative patient outcomes and vastly superior industrial ROI. Today the proof is clear that ONLY a therapy launch properly aligned with the right testing pathway delivers on the true health and economic promise of precision medicine. In Founding Diaceutics some 20 years ago, Peter combined his experiences of working both in the Pharmaceutical industry with GSK and the Diagnostics industry with Diagnology to forge a new business model, one focused on the reintegration of testing and treatment commercialization to radically improve patient outcomes. Diaceutics works today with over 40 therapy companies working at the front line of precision medicine. Meet Peter @ #Sachs_HTIF More Info @ https://lnkd.in/egY93Zys #HealthTech #MedTech #DigitalHealth #HealthcareInnovation #MedTechInvestment #MedicalDevices #BigData #PrecisionMedicine #InvestmentForum #investment #funding #Partnering #BusinessDevelopment #Networking #HealthTechStartups #InvestmentOpportunities #SachsAutumnLifeSciencesWeek #SALSW #startup #entrepreneur #earlystage

#fundingalert 💼Company: Valisure 💰Funding: Undisclosed Amount ⚡Round: New Round 👥Investors: AlleyCorp Valisure was founded by Adam Clark-Joseph, David Y. Light(ex-CEO). The company plans to use the money to grow its team of #specialists, speed up research and development, and solidify its position as the industry leader in independent #pharmaceutical quality assurance. Valisure’s team of scientists, trained at Harvard and Yale, developed proprietary #analytical #technologies to test products independently, identify critical issues, and provide services to help differentiate quality stakeholders and products in response to growing concerns and quality issues in the global supply chain. Jill Nailor, RPh, Karrah Goldberg, MPS, Kaury Kucera Read more - https://lnkd.in/g2bgtCJ7 To share your startup story write us on - contact@startuprise.io #valisure #scientist #pharmaceutical #health #funding #startup

#InCaseYouMissedIt EDDC, co11ab Novena and SGInnovate jointly organized a seminar titled “Advancing Drug Discovery to New Heights with Industry-Leading Technology Platforms” last Thursday on 27 July. Director of EDDC Academic Research Organization (EARO) Christophe Bodenreider shared about the various solutions that EARO can offer to assist researchers in their drug discovery project, including leveraging EDDC's state-of-the-art platform technologies to create customized solutions. He also participated in the panel discussion that followed, featuring a curated lineup of representatives from both the industry and academia. The panelists discussed various topics that were relevant to future bioentrepreneurs. This included lessons learnt from their own experience, such as how to avoid pitfalls when building partnerships and intellectual property strategy. They also painted a picture of the current landscape of the biotech ecosystem in Singapore and highlighted potential areas with opportunities for funding. It's been great working with co11ab Novena and SGInnovate to create such an engaging and informative session. #EDDCsg #DrugDiscovery #Collaboration #Seminar

*** WEBINAR *** on MethotrexateForte as investment opportunity sign-up by clicking this link: https://lnkd.in/dn-NDHr5 Join us at our upcoming #webinar with Capital Cell on Thursday the 23rd of November at 18:00 (CET) with #methotrexate #experts Maja Bulatović-Ćalasan and Maartje van de Meeberg: At the webinar, we will discuss the added value of #MethotrexateForte and the opportunity to join our efforts through the #crowdfunding opportunity through Capital Cell: https://lnkd.in/dW5rb8mU Please remember that although investing in life science ventures does come with risks, there are ways to minimize/eliminate certain risks. Both Amplio Pharma and its candidate drug product #MethotrexateForte have been rigorously scrutinized by the #duediligence partners of Capital Cell: BioExpert Network, Alira Health, Elion IP and RCD. Previous to this round we successfully went through the due dilligence process of Libertatis Ergo Holding B.V. the investment fund of the Leiden University. In addition, all components of #MethotrexateForte have already been tested and found safe in humans, the principle has been shown to result in an improved clinical outcome and our discovery is patent protected. Our core team of the 3 female founders is extended with experts from the field ranging from #doctors who use methotrexate as the anchor treatment in their clinical practice to #pharmacists who are experts in formulation of drug substances into drug products, so that we can successfully develop #MethotrexateForte.

In the medical diagnostics field, Hummsa Biotech (Backed by 100X.VC) Biotech revolutionizes testing with its InsGen IVD kit, which uses aptamer technology for high precision and rapid results in just 10 minutes. Founded by Harshad Lalwani and led scientifically by Dr. Swapnil Sinha, the company combines affordability, stability, and innovation. The global aptamer market, projected to grow significantly, supports Hummsa's vision of enhanced diagnostic accuracy and accessibility. With eco-friendly production and strategic partnerships, Hummsa Biotech is poised to lead the shift toward faster, precise point-of-care diagnostics. #HummsaBiotech #MedicalDiagnostics #AptamerTechnology #InsGen #HealthcareInnovation #RapidTesting #DiagnosticAccuracy #PointOfCare #SustainableHealthcare #BiotechLeadership #startup77